EMA Authorised: Simponi (golimumab) — Janssen Cilag International NV

View source ↗

Summary

The European Medicines Agency authorised Simponi (golimumab) for multiple inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Simponi (golimumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Arthritis, Rheumatoid. MAH: Janssen Cilag International NV. Decision date: 19/01/2026